Phase II Study of Panitumumab with Fluorouracil in Patients With KRAS Wild-type Metastatic Colorectal Cancer(PF Study)

Trial Profile

Phase II Study of Panitumumab with Fluorouracil in Patients With KRAS Wild-type Metastatic Colorectal Cancer(PF Study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Fluorouracil (Primary) ; Panitumumab (Primary) ; Capecitabine; Folinic acid; Gimeracil/oteracil/tegafur; Tegafur/uracil
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 09 Jun 2012 Additional lead investigator (Hideyuki Mishima) identified as reported by University Hospital Medical Information Network - Japan record.
    • 04 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top